Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Classical hematology 1CNS 1

Conditions

Sedentary Behavior 1Multiple Endocrine Neoplasia Type 1 1Insulin Resistance 1Hyperlipidemias 1Hyperglycemia 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ziprasidone × Endocrine × Clear all
NCT00910988 2018-07-18

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

Washington University School of Medicine

Phase NA Completed
46 enrolled 38 charts
Endocrine

Hyperglycemia, Hyperlipidemias, Insulin Resistance, Multiple Endocrine Neoplasia Type 1, Sedentary Behavior

Data powered by HemOnc (CC BY 4.0) Colophon âš¡